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The Renal sodium-dependent glucose co-transporter 2 (SGLT2) is one of the most
promising targets for the treatment of type 2 diabetes. Two SGLT2 inhibitors, dapagliflozin,
and canagliflozin, have already been approved for use in USA and Europe; several additional
compounds are also being developed for this purpose. Based on the in vitro IC50 values
and plasma concentration of dapagliflozin measured in clinical trials, the marketed dosage
of the drug was expected to almost completely inhibit SGLT2 function and reduce glucose
reabsorption by 90%. However, the administration of dapagliflozin resulted in only 30–50%
inhibition of reabsorption. This study was aimed at investigating the mechanism underlying
the discrepancy between the expected and observed levels of glucose reabsorption. To
this end, systems pharmacology models were developed to analyze the time profile of
dapagliflozin, canagliflozin, ipragliflozin, empagliflozin, and tofogliflozin in the plasma and
urine; their filtration and active secretion from the blood to the renal proximal tubules;
reverse reabsorption; urinary excretion; and their inhibitory effect on SGLT2. The model
shows that concentration levels of tofogliflozin, ipragliflozin, and empagliflozin are higher
than levels of other inhibitors following administration of marketed SGLT2 inhibitors at
labeled doses and non-marketed SGLT2 inhibitors at maximal doses (approved for phase
2/3 studies). All the compounds exhibited almost 100% inhibition of SGLT2. Based on the
results of our model, two explanations for the observed low efficacy of SGLT2 inhibitors
were supported: (1) the site of action of SGLT2 inhibitors is not in the lumen of the kidney’s
proximal tubules, but elsewhere (e.g., the kidneys proximal tubule cells); and (2) there are
other transporters that could facilitate glucose reabsorption under the conditions of SGLT2
inhibition (e.g., other transporters of SGLT family).
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a metabolic disorder that is
characterized by hyperglycemia resulting from insulin resistance
and relative lack of insulin. Current therapies for T2DM pri-
marily address endocrine pathogenesis of insulin resistance and
b-cell dysfunction. Consequently, many patients receive multi-
ple glucose-lowering therapies and eventually require exogenous
insulin administration. However, in clinical practice patients
often fail to meet the targets for glycemic control (Ali et al.,
2013), most frequently because of adverse effects–including
hypoglycemia and weight gain–caused by therapeutic agents
(Neumiller, 2014). Therefore, in order to avoid direct influence
on insulin resistance and b-cell dysfunction, T2DM can be treated
with inhibition of glucose reabsorption.
Glucose is reabsorbed to blood in the proximal tubules of
the kidneys during the formation of primary urine. Where the
reabsorption process is inhibited, glucose is excreted in urine
and blood glucose concentration is reduced. Patients treated
with inhibition of glucose reabsorption have a low risk of hypo-
glycemia because the mechanism of the treatment is independent
of insulin release or endogenous glucose production (Misra,
2013). In the kidneys, families of glucose transporters and
sodium-dependent glucose co-transporters are involved in glu-
cose reabsorption. For example, sodium-dependent glucose co-
transporter 2 (SGLT2) is thought to contribute to 90% of glucose
reabsorption in kidneys (Liu et al., 2012), which makes it a
promising target in T2DM therapy.
Currently, two SGLT2 inhibitors are marketed (dapagliflozin,
canagliflozin) and several more are in development (e.g.,
empagliflozin, tofogliflozin). Based on inhibitory concentra-
tion 50% (IC50) values measured in vitro (Ohtake et al.,
2012) and plasma concentrations measured in clinical tri-
als (Yang et al., 2013), the marketed dosage of dapagliflozin
was predicted to inhibit SGLT2 almost completely and thereby
reduce glucose reabsorption by 90%. However, clinical tri-
als demonstrated that dapagliflozin induced 50–80 g of uri-
nary glucose excretion per day, which corresponded to only
30–50% inhibition of reabsorption (Komoroski et al., 2009a;
Kasichayanula et al., 2011a). To explain these findings, several
hypotheses were published (Liu et al., 2012). The following
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hypotheses explain the lower than predicted efficacy of SGLT2
inhibitors:
(1) The concentration of the compound in the lumen of the kid-
ney’s proximal tubules (the potential site of inhibition) is
low.
(2) The site of action of the SGLT2 inhibitors is in the proximal
tubule cells of the kidney, but not in the lumen.
(3) Other transporters facilitate glucose reabsorption under con-
ditions of SGLT2 inhibition.
To explore these hypotheses further, it is possible to adopt a
systems pharmacology modeling (SPM) approach.
Many mathematical models that describe development and
treatment of T2DM appear in the literature, and Ajmera et al.
(2013) present a detailed review of these models. Several math-
ematical models describing SGLT2 inhibitors are also presented.
For example, three models describe the pharmacokinetics (PK)
and pharmacodynamics (PD) of SGLT2 inhibitors in animals
(Yamaguchi et al., 2011, 2012, 2013), two population PK mod-
els exist for empagliflozin (Riggs et al., 2013) and dapagliflozin
(van der Walt et al., 2013), and Maurer et al. (2011) describes a
PK/PD model for dapagliflozin in rats and humans. However, a
model that describes the concentration of SGLT2 inhibitors at the
potential site of action (i.e., the lumen of proximal tubule in the
kidneys) is yet to be published. The level of a compound in plasma
may differ significantly from that in the kidneys; therefore, pre-
diction of the concentration of SGLT2 inhibitors in the lumen of
the kidney’s proximal tubules is important for understanding the
PD effect of the drug.
The aim of this study was to construct a model that describes
the active secretion of SGLT2 inhibitors from plasma into the
lumen of the proximal tubules, reverse reabsorption, and urinary
excretion. Using an SPM approach, our objective was to test the
hypotheses used to explain the discrepancy between expected and
observed levels of glucose reabsorption following administrations
of SGLT2 inhibitors (see above). We also aimed to compare the
efficacies of different SGLT2 inhibitors by simulating their con-
centration level in the lumen of the kidney’s proximal tubules and
estimating the level of inhibition produced during treatment in
humans.
METHODS
A family of semi-mechanistic PK/PD models was developed
to describe administration, degradation, transport, glomerular
filtration, active secretion, reverse reabsorption, and urinary
excretion of 5 SGLT2 inhibitors (dapagliflozin, canagliflozin,
ipragliflozin, empagliflozin, tofogliflozin). The assumptions used
for model development are presented in Table 1. The models
describe the PK of the drugs, inhibition of glucose reabsorp-
tion mediated by SGLT2, and levels of inhibition in transporters
of the SGLT family. The models for dapagliflozin, ipragliflozin,
and tofogliflozin, which have identical structures, include 4 com-
partments: plasma, peripheral compartment (tissues, organs),
lumen of the kidney’s proximal tubules, and urine. The models
for canagliflozin and empagliflozin have the same structure and
include 3 compartments: plasma, lumen of the kidney’s proximal
tubules, and urine. The rate equations for each model are similar,
but many of the parameter values are specific to a particular drug.
We chose to add the peripheral compartment, and a rate equation
describing transport between plasma and peripheral compart-
ment, to models describing activity of dapagliflozin, ipragliflozin,
and tofogliflozin in order to achieve a better description of
plasma PK data (see “Models verification strategy” Section in
Supplementary Materials). The effects of compounds on SGLT2
and other transporters are described as functions of inhibitor con-
centration in the lumen of the kidney’s proximal tubules. Schemes
of the models are presented in Figure 1. Using the family of
models, we were able to quantify, analyze, and compare PK and
PD characteristics of the drugs. A system of ordinary differen-
tial equations, rate equations, and explicit functions are presented
in Table 2. Model development and fitting procedures were per-
formed using the DBSolve Optimum package (Gizzatkulov et al.,
2010).
IDENTIFICATION OF MODEL PARAMETERS
The strategy of model verification is presented in the
Supplementary Materials. The dapagliflozin, ipragliflozin,
and tofogliflozin models include 19 parameters: 4 physiological,
9 drug specific PK, and 6 drug specific PD. In the right hand
side of canagliflozin or empagliflozin models, 17 parameters are
included: 4 physiological, 7 drug specific PK, and 6 drug specific
PD. The parameter values are specific to each SGLT2 inhibitor
model, with the exception of 4 physiological parameters (Vplasma,
Vlumen, GFR, and Qurine) that have equal values in each model.
The physiological parameter values were taken (or calculated)
from the literature, as were those for 2 PK parameters (F and
fup) and 6 PD parameters (IC50 for SGLT1–6). The remaining 7
or 5 parameters were fitted against PK data on the dynamics of
compounds in plasma and urine. The 95% confidence intervals
Table 1 | Assumptions for models development.
# Assumption
1 There is active secretion of compounds from blood to the lumen of the kidney’s proximal tubules and reverse reabsorption (Liu et al., 2012)
2 Only an unbound drug could be filtrated or secreted from plasma to the lumen of the kidneys
3 The urinary excretion (Qurine) is similar for all compounds
4 Delay (lag) in absorption (Nerella et al., 1993; van der Walt et al., 2013) is included in all models to create a more precise description of plasma PK
data
5 The site of action for SGLT2 inhibitors is in the lumen of the kidney’s proximal tubules
6 The maximal inhibition level of SGLT2 (Imax) induced by compounds is equal to 1 (100%) (Grempler et al., 2012)
7 All rate equations are to be described as mass action law
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FIGURE 1 | Model Scheme. The model describes oral drug
administration, degradation, transport between plasma and
peripheral compartment (for dapagliflozin, ipragliflozin, and
tofogliflozin), glomerular filtration, secretion from plasma to the
lumen of the kidney’s proximal tubules, reverse reabsorption, and
urinary excretion.
were calculated for fitted parameters. Parameter values, 95% con-
fidence intervals, and the source of data for their identification
are presented in Supplementary Table 1.
COMPARTMENT VOLUMES
Volume of blood plasma was taken from the literature. The
volume of the lumen of the kidney’s proximal tubules was cal-
culated using experimental data (see Supplementary Materials).
In the models that described dapagliflozin, ipragliflozin, and
tofogliflozin, distribution volume in peripheral compartments
was fitted against PK data. Compartment volumes and the source
of identification are presented in Supplementary Table 1.
SIMULATIONS
Model simulations are presented as curves (simulated with opti-
mal parameters values) with shadows (95% confidence bands) or
as bars (simulated with optimal parameters values) with error
bars (95% confidence bands). The description of simulating
the 95% confidence bands is presented in the Supplementary
Materials.
RESULTS
All data available in the literature was used for model verification
and validation (Table 3). Models were calibrated against clinical
data obtained in trials where a single dose of SGLT2 inhibitor
was administered. By applying the verification strategy described
in the Supplementary Materials, we found that: (i) the active
secretion of dapagliflozin, canagliflozin, and ipragliflozin from
plasma to kidney lumen was equal to zero; (ii) the reabsorption
of empagliflozin was equal to zero; and (iii) both active secre-
tion and reabsorption of tofogliflozin were equal to zero. The
appropriate choice of model parameters was validated against
data obtained from single and multiple dose administration.
Figures 2, 3 represent examples of dapagliflozin model calibra-
tion using plasma PK and urine recovery data respectively, where
data was obtained from single dose trials. Figures 4, 5 also rep-
resent examples of dapagliflozin model validation against plasma
PK and urine recovery data respectively, but data was obtained
frommultiple dose trials. The 95% confidence bands captured the
variability in clinical data (Figures 4, 5); therefore, we concluded
that model validation was of satisfactory quality. Several addi-
tional figures demonstrating the quality of verification and vali-
dation in dapagliflozin, canagliflozin, ipragliflozin, empagliflozin,
and tofogliflozin models are presented in the Supplementary
Materials (Supplementary Figures 1–16). These figures demon-
strate that the models enable a satisfactory description of plasma
PK and recovery of SGLT2 inhibitors in urine.
CONCENTRATION OF SGLT2 INHIBITORS IN THE LUMEN OF THE
KIDNEY’S PROXIMAL TUBULES
To analyze and compare the concentration of drugs in the
lumen of the kidney’s proximal tubules–the predicted site of
inhibition–we simulated time profiles of the drugs resulting
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Table 2 | Differential equations, rate equations and explicit functions.
# Equation Description
DIFFERENTIAL EQUATIONS
D1 d (drugint )
dt
= −Rabs
Drug amount (mg) in intestine (drugint ).
There is a fixed delay in absorption (lagabs) implemented in the model
explicitly in accordance with method proposed by (Nerella et al., 1993).
Initial conditions:
drugint
(
0 < t < lagabs
) = 0,
drugint
(
t = lagabs
) = F*Dose
where F and Dose are bioavailability of a drug and dose administered
D2
d
(
Drugpls
)
dt
= (Rabs − Rdeg − Rpls_to_prf − Rgfr
− Rsecretion + Rreabsorption)/Vplasma
Drug concentration (mg/L) in plasma (Drugpls). Initial conditions:
Drugpls (0) = 0
D3
d
(
Drugprf
)
dt
= (Rpls_to_prf )/Vdprf
Drug concentration (mg/L) in peripheral compartment (Drugprf ). The
variable and rate equation Vpls_to_prf are included in dapagliflozin,
ipragliflozin and tofogliflozin models only. Initial conditions:
Drugprf (0) = 0
D4
d
(
Druglum
)
dt
= (Rgfr + Rsecretion
− Rreabsorption − Rurine)/Vlumen
Drug concentration (mg/L) in kidneys proximal tubules lumen (Druglum).
Initial conditions:
Druglum (0) = 0
D5
d
(
drugurine
)
dt
= Rurine
Drug amount (mg) in urine (drugurine). Value of the variable is set equal to
zero each 24 h to calculate amount of compound recovered in urine during
24 h. Initial conditions:
drugurine (0) = 0
RATE EQUATIONS
R1 Rabs = kabs*drugint Drug absorption from gastrointestinal tract
R2 Rdeg = Vplasma*kdeg*fup*Drugpls Drug degradation / metabolism in plasma
R3 Rpls_to_prf = Qprf *(fup*Drugpls − Drugprf ) Drug transport between plasma and peripheral compartment
R4 Rgfr = GFR*fup*Drugpls Drug glomerular filtration
R5 Rsecretion = Vplasma*ksec*fup*Drugpls Drug secretion from plasma to kidneys proximal tubules lumen
R6 Rreabsorption = Vlumen*kreab*Druglum Drug reabsorption from kidneys proximal tubules lumen into plasma
R7 Rurine = Qurine*Druglum Drug urinary excretion
EXPLICIT FUNCTIONS
E1 Drugng/mlplasma_total = Drugpls*103 Drug concentration in plasma (ng/ml)
E2 DrugnMlumen =
Druglum
Mr
*106 Drug concentration in kidneys proximal tubules lumen (nM). Mr – molecular
weight of compound
E3 Inhibition of glucose reabsorption mediated by SGLT2
= SGLT2%inhibition_level =
= DrugnMlumen
IC50sglt2 +DrugnMlumen
*100
Inhibition of glucose reabsorption mediated by SGLT2. SGLT2 inhibition
level. Similar expressions are true for description of inhibition level of other
transporters with corresponding IC50 values
E4 SGLT2%average_inhibition_level =
∫ t2
t1 SGLT2
%
inhibition_level
t2 − t1 Average inhibition level of SGLT2 during some period of time (from t1 to t2)
from oral administration at various dosages. Figure 6 demon-
strates that concentration levels of tofogliflozin, ipragliflozin, and
empagliflozin are higher than levels of other inhibitors following
administration of marketed SGLT2 inhibitors at labeled doses and
non-marketed SGLT2 inhibitors at maximal doses (approved for
phase 2/3 studies).
In order to investigate which of five compounds is most likely
to accumulate at the potential site of action, we also simulated
concentration levels of SGLT2 inhibitors in the lumen of the kid-
ney’s proximal tubules following a standardized dosage of the
compounds equal to 20mg. In this scenario, the model predicted
that concentrations of empagliflozin and tofogliflozin were higher
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Table 3 | Amount of data used for model verification and validation.
Compound Verification Validation
Number of Number of Number of Number of
experimental articles experimental articles
points points
Dapagliflozin 127 9 315 5
Canagliflozin 45 1 79 2
Empagliflozin 158 7 240 5
Ipragliflozin 45 2 210 1
Tofogliflozin 24 2 – –
FIGURE 2 | Example of verification of the dapagliflozin model using
plasma data. Total level of dapagliflozin in plasma following simulation of a
single administration of 50mg. Curve represents model simulation and dots
represent experimental data. Colors of dots correspond to different data
sources: black—Kasichayanula et al. (2011b), blue—Obermeier et al. (2010).
than the levels of dapagliflozin, canagliflozin, and ipragliflozin
(Supplementary Figure 17).
We also simulated and compared time profiles of SGLT2
inhibitor concentrations in plasma and lumen of the kidney. For
all SGLT2 inhibitors, our model predicted that the concentra-
tion in the lumen of the kidneys was higher than in plasma
(Figures 7, 8, Supplementary Figures 18–20).
LEVELS OF SGLT2 INHIBITION DURING TREATMENT WITH SGLT2
INHIBITORS
We simulated the average level of inhibition of glucose
reabsorption mediated by SGLT2 and compared our
findings with experimentally measured levels of glucose
reabsorption inhibition following treatment with com-
pounds (Figures 9, 10, Supplementary Figures 21–23). In
model simulations, the average level of inhibition of glu-
cose reabsorption mediated by SGLT2 was higher than the
FIGURE 3 | Example of verification of the dapagliflozin model using
urine data. Cumulative amount of dapagliflozin recovered in urine following
simulation of a single administration of 50mg. Curve represents model
simulation and dots represent experimental data. Colors of dots
correspond to different data sources: black—Obermeier et al. (2010); blue—
Kasichayanula et al. (2011a); red—Kasichayanula et al. (2013).
FIGURE 4 | Example of validation of the dapagliflozin model using
plasma data. Total level of dapagliflozin in plasma following simulation of a
single administration, but at different doses (Yang et al., 2013). Curve
represents model simulations and dots represent experimental data. Colors
of curves and dots correspond to the different doses: black—5mg,
blue—10mg. Model simulations are presented with 95% confidence bands.
level of total glucose reabsorption inhibition, and almost
equal to 100%, following treatment with all experimental
doses of SGLT2 inhibitors (Figures 9, 10, Supplementary
Figures 21–23).
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FIGURE 5 | Example of validation of the dapagliflozin model using
urine data. Amount of dapagliflozin recovered in urine every 24 h following
simulation of multiple administrations of 10mg QD. Curve represents
model simulation and dots represent experimental data. Colors of dots
correspond to the different data sources: black—Kasichayanula et al.
(2011a), blue—Yang et al. (2013). Model simulation is presented with 95%
confidence bands.
To compare the efficacies of each compound, the level of
SGLT2 inhibition was simulated after administration of equal
doses (20mg) (Supplementary Figure 24), labeled doses of mar-
keted inhibitors, and maximal doses of other inhibitors approved
for phase 2/3 studies (Figure 11). For all compounds, adminis-
tration of equal or labeled/maximal approved doses resulted in
almost 100% inhibition of SGLT2. Therefore, the difference in
efficacy of the tested SGLT2 inhibitors was not significant.
EFFECT OF SGLT2 INHIBITORS ON OTHER TRANSPORTERS FROM THE
SGLT FAMILY
To predict the effect of dapagliflozin, canagliflozin, ipragliflozin,
empagliflozin, and tofogliflozin on other members of the SGLT
family, the inhibition level of these transporters in the lumen of
the kidney’s proximal tubules was simulated following admin-
istration of labeled doses of marketed inhibitors and maxi-
mal doses of other inhibitors approved for phase 2/3 studies.
We found that the influence of the inhibitors on other trans-
porters was substantial–approximately 50% or above for par-
ticular compounds (Supplementary Figure 25–29). The most
effective inhibitor of SGLT1 was canagliflozin (Supplementary
Figure 25), while ipragliflozin and tofogliflozin produced the
strongest inhibition of SGLT3 (Supplementary Figure 26).
While all other SGLT2 inhibitors have a similar effect on
SGLT4, dapagliflozin is a weak inhibitor of this co-transporter
(Supplementary Figure 27). Ipragliflozin and empagliflozin are
the strongest SGLT5 inhibitors (Supplementary Figure 28), while
canagliflozin has the strongest effect on SGLT6 (Supplementary
Figure 29).
FIGURE 6 | Concentration of SGLT2 inhibitors in the lumen of the
kidney’s proximal tubules. Level of SGLT2 inhibitors in the lumen of the
kidney’s proximal tubules following simulation of multiple administrations of
labeled doses of marketed SGLT2 inhibitors and maximal doses of other
SGLT2 inhibitors approved for phase 2/3 studies. Colors of curves
correspond to different compounds: black—10mg QD dapagliflozin;
blue—300mg QD canagliflozin; red—25mg QD empagliflozin;
green—300mg QD ipragliflozin; pink—40mg QD tofogliflozin. Model
simulations are presented with 95% confidence bands.
FIGURE 7 | Concentration of dapagliflozin in plasma and the lumen
of the kidney’s proximal tubules. Dapagliflozin levels found in different
compartments following simulation of a single administration of 10mg.
Colors of curves correspond to various compartments. Black—total
plasma concentration; blue—unbound plasma concentration;
red—concentration in lumen. Model simulations are presented with 95%
confidence bands.
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DISCUSSION
SGLT2 is a promising target for the treatment of T2DM because
its inhibition could lower glucose levels without directly influ-
encing insulin resistance or b-cell function. However, in a
FIGURE 8 | Concentration of tofogliflozin in plasma and the lumen of
the kidney’s proximal tubules. Tofogliflozin levels found in different
compartments following simulation of a single administration of 40mg.
Colors of curves correspond to various compartments. Black—total plasma
concentration; blue—unbound plasma concentration; red—concentration in
lumen. Model simulations are presented with 95% confidence bands.
previous study, administration of SGLT2 inhibitors resulted in
only 30–50% inhibition of glucose reabsorption in human sub-
jects even at high doses, which was in contrast to the expected
inhibition of 90% based on in vitro potency and plasma levels
(Liu et al., 2012). In our study, we applied a systems pharmacol-
ogy modeling approach to test several hypotheses that attempt to
explain the discrepancy between the expected and observed lev-
els of glucose reabsorption following administration of SGLT2
inhibitors. We developed models, simulated concentrations of
SGLT2 inhibitors in the lumen of the kidney’s proximal tubules,
and compared the efficacy of these compounds in terms of levels
of in vivo SGLT2 inhibition.
Models for SGLT2 inhibitors were verified and validated
against all available clinical data describing the PK of the com-
pounds in plasma and urine. Similar to the model of Maurer
et al. (2011), we introduced a peripheral compartment into
our model of dapagliflozin. We also included this compartment
for ipragliflozin and tofogliflozin models. Despite the inclusion
of a peripheral compartment in a previously published model
of empagliflozin (Riggs et al., 2013), we chose a model with-
out peripheral compartment for empagliflozin based on Akaike
Information Criterion (AIC) (Akaike, 1974). The AIC we cal-
culated for the empagliflozin model without a peripheral com-
partment was lower than that of the model with peripheral
compartment (343 vs. 345, respectively). Our canagliflozin model
was also developed on the basis of one compartmental PK model.
Applying a verification strategy described in the
Supplementary Materials, we were able to estimate the models’
parameter values for active secretion of the drugs from plasma
to urine and reabsorption from urine to plasma. Indeed, we
found that the active secretion from plasma to the lumen of the
FIGURE 9 | Comparison of simulated average inhibition of glucose
reabsorption mediated by SGLT2 and clinically measured glucose
reabsorption inhibition levels during treatment with dapagliflozin.
Comparison of the average inhibition of glucose reabsorption mediated by
SGLT2 (simulated in the model) and levels of glucose reabsorption inhibition
(measured in experiment) on the 14th day following multiple administrations
of different doses of dapagliflozin (Komoroski et al., 2009a). Model
simulations are presented with 95% confidence bands.
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FIGURE 10 | Comparison of simulated average inhibition of glucose
reabsorption mediated by SGLT2 and clinically measured glucose
reabsorption inhibition levels during treatment with empagliflozin.
Comparison of the average inhibition of glucose reabsorption mediated by
SGLT2 (simulated in the model) and levels of glucose reabsorption inhibition
(measured in experiment) on the 1st day after multiple administrations of
different doses of empagliflozin (Heise et al., 2013a). Model simulations are
presented with 95% confidence bands.
kidneys was equal to zero for dapagliflozin, canagliflozin, and
ipragliflozin, but non-zero reabsorption should be taken into
account to describe available clinical data. The reabsorption
of empagliflozin was equal to zero, but non-zero secretion
contributes substantially to the balance of the drug between
plasma and urine. Both active secretion and reabsorption of
tofogliflozin were equal to zero. Plasma and urine PK data
are not sufficient to evaluate the unique values of the rate
constants that are responsible for reabsorption and secretion
simultaneously. These two parameters are correlated with each
other. For tofogliflozin, there is lack of clinical data available
to evaluate at least one of these parameters. To understand
whether the uncertainty in these parameter values affects the
description of clearance in the model, the total systemic and
renal clearances measured in clinical trials were compared with
those calculated in the model. The total systemic clearance of
dapagliflozin was 265mL/min in the model and 207mL/min
in clinical trials (Boulton et al., 2013). The renal clearance of
dapagliflozin was 3.95mL/min in the model and 3–5mL/min
in clinical trials (Komoroski et al., 2009a,b; Kasichayanula et al.,
2011a). The renal clearances of empagliflozin and ipragliflozin
in the model were 35 and 1.88mL/min respectively, while they
were 30–37mL/min for empagliflozin (Heise et al., 2013a,b) and
1–3mL/min for ipragliflozin (Veltkamp et al., 2011; Zhang et al.,
2013) in clinical data. The total systemic clearance of tofogliflozin
was equal to 9.9 L/h in the model and 10 L/h in clinical tri-
als (Schwab et al., 2013). The renal clearance of tofogliflozin
was equal to 20mL/min in the model and 25.7mL/min in
clinical trials (Schwab et al., 2013). Therefore, the values pro-
duced by our models are similar to experimentally measured
values.
FIGURE 11 | Levels of SGLT2 inhibition after drug administration.
Levels of SGLT2 inhibition following simulation of multiple administrations
of labeled doses of marketed SGLT2 inhibitors and maximal doses of other
SGLT2 inhibitors approved for phase 2/3 studies. Colors of curves
correspond to different compounds: black—10mg QD dapagliflozin;
blue—300mg QD canagliflozin; red—25mg QD empagliflozin;
green—300mg QD ipragliflozin; pink—40mg QD tofogliflozin. Model
simulations are presented with 95% confidence bands.
One hypothesis proposed by Liu et al. (2012) states that the
low efficacy of SGLT2 inhibitors could be explained by the low
concentration of compounds at the potential site of action–the
lumen of kidney’s proximal tubules. Our model suggests that
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concentrations of SGLT2 inhibitors in the lumen are higher than
the corresponding unbound and total concentrations in plasma.
This can be explained in terms of reabsorption of water in kid-
ney’s proximal tubules (Panchapakesan et al., 2009). A decrease in
water volume in the lumen leads to an increase in the concentra-
tion of the compounds in lumen than in the plasma. In themodel,
this is reflected by the ratio of glomerular filtration and urine
excretion (urine formation) rates. Thus, we conclude that the
concentration of compounds in the lumen of the kidney’s proxi-
mal tubules is actually relatively high, and we reject the hypothesis
that the low efficacy of SGLT2 inhibitors is caused by their low
concentration at the site of action. Our model predicts that con-
centrations of empagliflozin and tofogliflozin in kidney lumen
are higher than concentrations of dapagliflozin, canagliflozin,
and ipragliflozin following administration of equal doses. This
prediction is supported by data obtained from clinical trials,
which indicates that approximately 20% of the empagliflozin and
tofogliflozin dose is recovered in urine (Brand et al., 2012; Zell
et al., 2013) in comparison to about 1% for the other SGLT2
inhibitors (Kasichayanula et al., 2011a; Devineni et al., 2013;
Zhang et al., 2013).
The model shows that administration of labeled doses of mar-
keted inhibitors (dapagliflozin and canagliflozin) and of maximal
doses approved for phase 2/3 studies of tofogliflozin, ipragliflozin,
and empagliflozin leads to almost complete inhibition of SGLT2
in vivo. The average inhibition level of glucose reabsorptionmedi-
ated by SGLT2 (the average SGLT2 inhibition level) predicted by
the model is higher than glucose reabsorption inhibition level
measured in clinical trials, and almost equal to 100%. Thus, if
the lumen of the kidney’s proximal tubules is indeed the site of
action of SGLT2 inhibitors, and SGLT2 is the main transporter
that facilitates reabsorption of glucose, then there is a contra-
diction between the simulations produced by the model and the
clinical data. This contradiction leads us to support two hypothe-
ses proposed by Liu et al. (2012). Firstly, that the potential site
of action of SGLT2 inhibitors is not in the lumen of the kidney’s
proximal tubules, but in the proximal tubule cells. Secondly, that
there are other transporters that could facilitate glucose reabsorp-
tion under the conditions of SGLT2 inhibition. Both hypotheses
appear reasonable within the framework of our current model.
To determine which of these two hypotheses is true, further
modeling supported by additional experimental data is required.
The model was applied to compare the efficacy of different
SGLT2 inhibitors in respect of inhibiting other transporters in the
SGLT family that are expressed in kidneys. Simulating the admin-
istration of equal doses of compounds (20mg), labeled doses
of marketed inhibitors, and maximal doses of other inhibitors
approved for phase 2/3 studies showed that levels of SGLT2 inhi-
bition are similar for all compounds and almost equal to 100%.
This is caused by high concentrations of SGLT2 inhibitors in
the lumen of the kidneys and low in vitro IC50 values. The
effect of SGLT2 inhibitors on other transporters is also rather
strong because of its high concentration in kidney’s lumen.
Canagliflozin is the strongest SGLT1 and SGLT6 inhibitor, and
this is caused by canagliflozin’s low IC50 (the lowest of all the
SGLT2 inhibitors considered here). The most effective SGLT3
inhibitors are ipragliflozin and tofogliflozin because of their high
in vitro potencies. All compounds have similar effects on SGLT4,
except dapagliflozin. Dapagliflozin has the weakest influence on
SGLT4 because of its low concentration in the kidney’s lumen.
Ipragliflozin and empagliflozin are the strongest SGLT5 inhibitors
because of their low IC50 of for SGLT5, and the high concentra-
tion of ipragliflozin in the lumen.
In conclusions, we have developed a systems pharmacology
model for SGLT2 inhibitors that enables the estimation of its con-
centration in the lumen of the kidney’s proximal tubules (the
potential site of SGLT2 action) and the prediction of SGLT2 inhi-
bition levels during treatment in humans. We have shown that
the concentration of SGLT2 inhibitors in the lumen of the proxi-
mal tubules is high, and that the level of SGLT2 inhibition during
treatment in humans is almost 100%. Based on the results of
our model, two explanations for the observed low efficacy of
SGLT2 inhibitors were supported: (1) the site of action of SGLT2
inhibitors is not in the lumen of the kidney’s proximal tubules, but
elsewhere (e.g., the kidneys proximal tubule cells); and (2) there
are other transporters that could facilitate glucose reabsorption
under the conditions of SGLT2 inhibition (e.g., other transporters
of SGLT family). It was found that all SGLT2 inhibitors have
similar efficacy.
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